<DOC>
	<DOC>NCT00151983</DOC>
	<brief_summary>This study will assess the safety and tolerability of MTS while attempting to establish the appropriate starting dose for subjects previously on an existing long-acting methylphenidate product.</brief_summary>
	<brief_title>Safety &amp; Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD &amp; Previously Treated With Extended-Release Methylphenidate Therapy</brief_title>
	<detailed_description>Attention-Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder characterized by 3 main symptoms: inattention, hyperactivity and impulsivity. This study will assess the safety and tolerability of SPD485 while attempting to establish the appropriate starting dose for subjects previously on an existing long-acting methylphenidate product.</detailed_description>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Subject must have a primary diagnosis of ADHD Subject must be adequately controlled on a stable dose of one of the following medications for a 30 day period: Ritalin LA(r), Concerta(r), or Metadate DC(r), not to exceed 54 mg per day Females of childbearing potential must have a negative serum beta Human Chorionic Gonadotropin pregnancy test A history of mental retardation that would indicate that the subject is not functioning at an age appropriate level intellectually A recent history of suspected substance abuse or dependence disorder Subject is taking Strattera Clinical signs and symptoms of skin irritation or hyper/hypopigmentation at the potential application sites</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>